Consequently, the effects of PPARγ on hepatic steatosis have not been conclusive, as the administration of PPARγ agonists in different animal models induces seemingly opposing effects, and the effects also differ between mice and humans, as well as among clinical studies. The gene discussed is PPARG; the disease is Hepatic steatosis.